Arg-Gly-Glu-Ser TFA | Cytiva思拓凡-Whatman滤纸滤膜滤器

Arg-Gly-Glu-Ser TFA; 纯度: 98.22%

Arg-Gly-Glu-Ser TFA 是一种与 RGD 有关的多肽，控制 RGDS 对纤维蛋白原与激活的血小板结合的抑制活动。

Arg-Gly-Glu-Ser TFA Chemical Structure

规格	价格	是否有货	数量
10;mM;*;1 mL in Water	￥1360	In-stock
2 mg	￥500	In-stock
5 mg	￥1100	In-stock
10 mg	￥1900	In-stock
25 mg	￥3900	In-stock
50 mg	￥6900	In-stock
100 mg	;	询价	;
200 mg	;	询价	;

* Please select Quantity before adding items.

Arg-Gly-Glu-Ser TFA 相关产品

bull;相关化合物库:

Bioactive Compound Library Plus
Peptidomimetic Library
Peptide Library

生物活性

Arg-Gly-Glu-Ser TFA is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

体内研究
(In Vivo)

Arg-Gly-Glu-Ser (5 mg/kg) in combination with LPS or saline + RGDS does not affect neutrophil and macrophage cell numbers and has no effect on protein accumulation compared with LPS- or saline-treated mice, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

561.47

Formula

C₁₈H₃₀F₃N₇O₁₀

Sequence

Arg-Gly-Glu-Ser

Sequence Shortening

RGES

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80deg;C	2 years
	-20deg;C	1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:;

H₂O : 20 mg/mL (35.62 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7810 mL	8.9052 mL	17.8104 mL
5 mM	0.3562 mL	1.7810 mL	3.5621 mL
10 mM	0.1781 mL	0.8905 mL	1.7810 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

参考文献

[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

Animal Administration ^[1]	Mice^[1] Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

Animal Administration
^[1]

Mice^[1]
Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.